HC Wainwright Raises Earnings Estimates for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – HC Wainwright increased their Q3 2026 EPS estimates for shares of Zenas BioPharma in a report released on Friday, August 14th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($1.31) for the quarter, up from their previous forecast of ($1.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Zenas BioPharma’s current full-year earnings is ($5.12) per share. HC Wainwright also issued estimates for Zenas BioPharma’s Q4 2026 earnings at ($1.31) EPS, FY2026 earnings at ($5.83) EPS, FY2027 earnings at ($5.11) EPS, FY2028 earnings at ($3.42) EPS, FY2029 earnings at ($2.72) EPS and FY2030 earnings at ($1.93) EPS.

A number of other brokerages have also commented on ZBIO. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Guggenheim reissued a “buy” rating and issued a $55.00 target price on shares of Zenas BioPharma in a research note on Friday. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Finally, Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $45.71.

Zenas BioPharma Price Performance

Shares of ZBIO stock opened at $30.50 on Tuesday. Zenas BioPharma has a 52 week low of $13.50 and a 52 week high of $44.60. The stock has a market capitalization of $1.99 billion, a PE ratio of -3.39 and a beta of -1.03. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. The stock’s fifty day moving average is $27.21 and its 200-day moving average is $23.48.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to analyst estimates of $15.00 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE acquired a new stake in shares of Zenas BioPharma during the second quarter worth $31,247,000. Jupiter Topco LLC acquired a new position in shares of Zenas BioPharma during the 2nd quarter worth about $201,000. J. Goldman & Co LP bought a new stake in shares of Zenas BioPharma in the 2nd quarter valued at about $1,732,000. Legal & General Group Plc bought a new stake in shares of Zenas BioPharma in the 2nd quarter valued at about $508,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Zenas BioPharma in the 2nd quarter valued at approximately $204,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.